Management of locally advanced and recurrent pancreas cancer

A. Jimeno, M. Hidalgo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pancreatic cancer remains a devastating disease. In 2007 the estimated incidence of the disease in the USA is 37,170 with an expected 33,370 deaths [1]. At the time of diagnosis, 80% of patients have locally advanced or advanced disease for which no curative therapy exist, and 80% of patients treated with curative intent will recur in the first 2 years after surgical resection and will succumb to their disease [2]. Locally advanced pancreatic cancer is usually defined as patients with American Joint Committee on Cancer (6th edition) T4 lesions, where the primary tumor involves branches of the celiac axis or the superior mesenteric artery, indicating an unresectable primary tumor and representing stage III disease. These patients often require operative or nonoperative palliation of disease-related processes such as obstructive jaundice, gastroduodenal obstruction, or abdominal pain. Focused anticancer treatment for such locally advanced pancreatic adenocarcinoma can involve chemoradiation approaches, chemotherapy alone, or locally directed therapy.

Original languageEnglish (US)
Title of host publicationDiseases of the Pancreas
Subtitle of host publicationCurrent Surgical Therapy
PublisherSpringer Berlin Heidelberg
Pages689-694
Number of pages6
ISBN (Print)9783540286554
DOIs
StatePublished - Dec 1 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Management of locally advanced and recurrent pancreas cancer'. Together they form a unique fingerprint.

Cite this